KussmaulAMaierR.Ueber eine bisher beschriebene eigenthumliche arterienerkrankung (periarteritis nodosa), die mit morbus brightii und rapid fortschrietender allgemeiner muskellahmung einhergeht. Dtsch Arch Kin Med1866; 1: 484–517.
2.
FauciASHaynesBFKatzP.The spectrum of vasculitis. Clinical, pathologic, immunologic, and therapeutic considerations. Ann Intern Med1978; 89: 660–76.
3.
ScottDGI. Classification and treatment of systemic vasculitis [Editorial]. Br J Rheumatol1988; 27: 251–57.
4.
LieJT. Classification and immunodiagnosis of vasculitis: A new solution or promises unfulfilled?J Rheumatol1988; 15: 728–32.
5.
ChurgJChurgA.Idiopathic and secondary vasculitis: A review. Mod Pathol1989; 2: 144–60.
6.
LiebermanKChurgA.Wegener's granulomatosis. In: ChurgAChurgJ.Systemic vasculitides. New York: Igaku-Shoin Medical Publishers Inc, 1991: 79–99.
7.
LanhamJGChurgJ.Churg-Strauss syndrome. In: ChurgAChurgJ.Systemic vasculitides. New York: Igaku-Shoin Medical Publishers Inc, 1991: 101–20.
8.
DavsonJBallJPlattR.The kidney in periarteritis nodosa. Q J Med1948; 17: 175–205.
9.
DonaldKJEdwardsRLMcEvoyJDS. An ultrastructural study of the pathogenesis of tissue injury in limited Wegener's granulomatosis. Pathology1976; 8: 161–69.
10.
NovakRFChristiansenRGSorensenET. The acute vasculitis of Wegener's granulomatosis in renal biopsies. Am J Pathol1982; 78: 367–71.
11.
D'AgatiVChandlerPNashMeMancilla-JimenezRM. Idiopathic microscopic polyarteritis nodosa: Ultrastructural observations on the renal vasculature and glomerular lesions. AM J Kidney Dis1986; 7: 95–110.
12.
SavageCOS. Pathogenesis of systemic vasculitis. In: ChurgAChurgJ.Systemic vasculitides. New York: Igaku-Shoin Medical Publishers Inc, 1991: 7–30.
13.
AlexanderELMoyerCFTravlosGSRothsJBMurphyED. Two histopathologic types of inflammatory vascular disease in MRL/MP autoimmune mice: Models for human vasculitis in connective tissue disease. Arthritis Rheum1985; 28: 1146–55.
14.
MoyerCFStrandbergJDReinischCL. Systemic mononuclear vasculitis in MRL/MP-1pr/1pr mice. A histologic and immunochemical analysis. Am J Pathol1987; 127: 229–42.
15.
MoyerCFReinischCL. The role of vascular smooth muscle cells in experimental autoimmune vasculitis. I: The initiation of delayed type hypersensitivity angiitis. Am J Pathol1984; 117: 380–90.
16.
BeredenJHMHangLMcConaheyJDixonFJ. Analysis of vascular lesions in murine SLE. I: Association with serologic abnormalities. J Immunol1983; 130: 1699–1705.
17.
MiyazawaMNoseMKawashimaMKyogokuM.Pathogenesis or arteritis of SL/Ni mice. Possible lytic effect of anti gp70 antibodies on vascular smooth muscle cells. J Exp Med1987; 87: 890–908.
18.
HartMNSadewasserKLCancillaPADebaultLE. Experimental autoimmune type of vasculitis resulting from activation of mouse lymphocytes to cultured endothelium. Lab Invest1983; 48: 419–27.
19.
HartMNTassellSKSadewasserKLSchelperRLMooreSA. Autoimmune vasculitis resulting from in vitro immunization of lymphocytes to smooth muscle. Am J Pathol1985; 119: 448–55.
20.
StanfordMRBrownECKasoEGrahamEMSandersMD. Experimental posterior uveitis I: A clinical angiographic and pathological study. Br J Ophthalmol1987; 71: 585–92.
21.
MathiesonPWEsnaultVIMThiruSOliveiraDBGLockwoodCM. An animal model of ANCA-positive systemic vasculitis. J Am Soc Nephrol1991; 2: 600.
22.
ReinischCLMoyerCF. Animal models of vasculitis. In: ChurgAChurgC.Systemic vasculitidesNew York: Igaku-Shoin Medical Publishers Inc, 1991: 31–40.
23.
EstesPCChevilleNF. The ultrastructure of vascular lesions in equine viral arteritis. Am J Pathol1970; 58: 235–53.
24.
PorterDDLarsenAE. Aleutial disease of mink: Infectious virus-antibody complexes in the serum. Proc Soc Exp Biol Med1967; 126: 680–82.
25.
BoespflugOGodfrainsCTardieuM.Effect of cyclosporin A on an experimental chronic viral infection of the central nervous system. J Neuroimmunol1989; 21: 49–57.
26.
LechmanTJAMahnovskiV.Animal models of vasculitis. Lessons we can learn to improve our understanding of Kawasaki disease. Rheum Dis Clin North Am1988; 14: 479–87.
27.
CochraneCGKofflerD.Immune complex disease in experimental animals and man. Adv Immunol1973; 16: 185–264.
FauciASHaynesBFKatzPWolffSM. Wegener's granulomatosis: Prospective and clinical therapeutic experience with 85 patients for 21 years. Ann Intern Med1983; 86: 76–85.
30.
BalowJEFauciAS. Vasculitic diseases of the kidney: Polyarteritis nodosa, Wegener's granulomatosis, allergic angiitis and granulomatosis, and other disorders. In: SchrierRWGottschalkCW. Diseases of the kidney, volume 2. Boston: Little, Brown and Co, 1988: 2335–60.
31.
PuseyCDReesAJEvansDJPetersDKLockwoodCM. A randomised controlled trial of plasma exchange in rapidly progressive glomerulonephritis: Evidence for benefit in dialysis dependent cases. Kidney Int1992 (in press).
32.
FurushoTKamiyaTNakanoH. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet1984; ii: 1055–58.
33.
JayneDRWDaviesMJFoxCJVBlackCMLockwoodCM. Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet1990; 337: 1137–39.
34.
DaviesDJMoranJENiallJFRyanGB. Segmental necrotizing glomerulonephritis with antineutrophil antibody: Possible arbovirus aetiology?Br Med J1982; 285: 606.
35.
HallJBWadhamBMWoodCJAshtonVAdamWR. Vasculitis and glomerulonephritis: A subgroup with antineutrophil cytoplasmic antibody. Aust N Z J Med1984; 14: 277–78.
36.
van der WoudeFJRasmussenNLobattoS. Autoantibodies against neutrophils and monocytes: Tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet1985; i: 425–29.
37.
SavageCOSWinearlsCGJonesSMarshallPDLockwoodCM. Prospective study of radioimmunoassay for antibodies against neutrophil cytoplasm in diagnosis of systemic vasculitis. Lancet1987; i: 1389–93.
38.
WathenCWHarrisonDJ. Circulating anti-neutrophil antibodies in systemic vasculitis. Lancet1987; i: 1037.
39.
SerraACameronJSTurnerDR. Vasculitis affecting the kidney: Presentation, histopathology and long-term outcome. Q J Med1984; 210: 181–207.
40.
FalkRJJenetteJC. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotising and crescentic glomerulonephritis. N Engl J Med1988; 318: 1651–57.
BlakeWall AWLLobattoSJongesLDahaMRvan EsLA. IgA antibodies directed against cytoplasmic antigens of polymorphonuclear leukocytes in patients with Henoch-Schoenlein purpura. Adv Exp Med Biol1987; 216b: 1593–98.
43.
GoldschmedingRvan der SchootCEten Bokkel HuininkD. Wegener's granulomatosis autoantibodies identify a novel diisopropylfluorphosphate-binding protein in the lysosomes of normal human neutrophils. J Clin Invest1989; 84: 1577–87.
44.
NilesJLMcCluskeyRTAhmadMFArnaoutMA. Wegener's granulomatosis autoantigen is a novel neutrophil serine proteinase. Blood1989; 74: 1888–93.
45.
LeungDYMGehaRSNewburgerJW. Two monokines, interleukin 1 and tumor necrosis factor, render cultured vascular endothelial cells susceptible to lysis by antibodies circulating during Kawasaki disease. J Exp Med1986; 164: 1958–72.
46.
LeungDYMCollinsTLapierreLAGehaRSPoberJS. Immunoglobulin M antibodies present in the acute phase of Kawasaki syndrome lyse cultured vascular endothelial cells stimulated by gamma interferon. J Clin Invest1986; 77: 1428–35.
47.
BrasileLKremerJMClarkeJLCerilliJ.Identification of an autoantibody to vascular endothelial cell-specific antigens in patients with systemic vasculitis. Am J Med1989; 87: 74–80.
48.
FerraroGMeroniPLTincaniA. Anti-endothelial cell antibodies in patients with Wegener's granulomatosis and micropolyarteritis. Clin Exp Immunol1990; 79: 47–53.
49.
SavageCOSPottingerBGaskinGLockwoodCMPuseyCDPearsonJ.Vascular damage in Wegener's granulomatosis and microscopic polyarteritis: Presence of anti-endothelial cell antibodies and their relation to anti-neutrophil cytoplasm antibodies. Clin Exp lmmuno. 1989; 85: 14–19.
50.
FramptonGJayneDRWPerryGJLockwoodCMCameronJS. Autoantibodies to endothelial cells and neutrophil cytoplasmic antigens in systemic vasculitis. Clin Exp Immunol. 1990; 82: 227–32.
51.
PoberJSCotranRS. Cytokines and endothelial cell biology. Physiol Rev1990; 70: 427–51.
52.
EwertBHJennetteJCFalkRJ. The pathogenic role of antineutrophil cytoplasmic autoantibodies. Am J Kidney Dis1991; 18: 188–95.
53.
ten BergeIJWilminkJMMeyerCJ. Clinical and immunological follow-up of patients with severe renal disease in Wegener's granulomatosis. Am J Nephrol1985; 5: 21–29.
54.
SpencerSJWBurnsAGaskinGPuseyCDReesAJ. HLA class II specificities and the development and duration of vasculitis with antibodies to neutrophil cytoplasmic antigens. Kidney Int1992 (in press).
55.
ToddJA. Genetic control of autoimmunity in type I diabetes. Immunol Today1990; 11: 122–29.
56.
NolleBSpecksULudemannJRohrbachMSDeRemeeRAGrossWL. Anticytoplasmic autoantibodies: Their immunodiagnostic value in Wegener's granulomatosis. Ann Intern Med1989; 111: 28–40.
57.
TervaertCohen JWHuitemaMGHeneRJ. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet1990; 336: 709–11.
58.
GaskinGSavageCOSRyanJJ. Antineutrophil cytoplasmic antibodies and disease activity during follow-up of 70 patients with systemic vasculitis. Nephrol Dial Transplant1991; 6: 689–94.
59.
CsernokELudemannJGrossWLBaintonDF. Ultrastructural localization of proteinase 3, the target antigen of anti-cytoplasmic antibodies circulating in Wegener's granulomatosis. Am J Pathol1990; 137: 1113–20.
60.
CaldasMLCharlesLAFalkRJJennetteJC. Immunoelectron microscopic documentation of the translocation of proteins reactive with ANCA to neutrophil cell surfaces during neutrophil activation [Abstract]. Am J Kidney Dis1991; 18: 204.
61.
FalkRJTerrellRSCharlesLAJennetteJC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA1990; 87: 4115–19.
FujimotoTLockwoodCM. Antineutrophil cytoplasm antibodies (ANCA) activate protein kinase C in human neutrophils and HL-60 cells [Abstract]. Am J Kidney Dis1991; 18: 204.
64.
WeissSJ. Tissue destruction by neutrophils. N Engl J Med1989; 320: 365–76.
WeissSYoungJLoBuglioASlivkaANimehN.Role of hydrogen peroxide in neutrophil mediated destruction of cultured endothelial cells. J Clin Invest1981; 68: 714–21.
67.
MartinWJ. Neutrophils kill pulmonary endothelial cells by a hydrogen peroxide-dependent pathway: An in vitro model of neutrophil-mediated lung injury. Am Rev Respir Dis1984; 130: 209–13.
68.
VaraniJFligielSEGTillGOKunkelRGRyanUSWardPA. Pulmonary endothelial cell killing by human neutrophils: Possible involvement of hydroxyl radical. Lab Invest1985; 53: 656–63.
69.
FantoneJCWardPA. Role of oxygen-derived free radicals and metabolites in leukocyte-dependent inflammatory reactions. Am J Pathol1982; 107: 397–427.
70.
TillGOJohnsonKJKunkelRWardPA. Intravascular action of complement and acute lung injury: Dependency of neutrophils and toxic oxygen metabolites. J Clin Invest1982; 69: 1126–35.
71.
SavageCOSPottingerBEGaskinGPuseyCDPearsonJD. Autoantibodies developing to myeloperoxidase and proteinase.3 in systemic vasculitis stimulate neutrophil cytotoxicity towards cultured endothelial cells. Am J Pathol1992 (in press).
72.
EwertBHJennetteJCFalkRJ. Anti-myeloperoxidase antibodies stimulate neutrophils to damage human endothelial cells. Kidney Int1992 (in press).
73.
HarlanJLevineJCallahanKSchwartzBHarkerL.Glutathione redox cycle protects cultured endothelial cells against lysis by extracellular generated hydrogen peroxide. J Clin Invest1984; 73: 706–13.
74.
HooverRLRobinsonJMKarnovskyMJ. Adhesion of polymorphonuclear leukocytes to endothelium enhances the efficiency of detoxification of oxygen-free radicals. Am J Pathol1987; 126: 258–68.
75.
BasfordREClarkRLStillerRAKaplanSSKuhnsDBRinaldoJE. Endothelial cells inhibit receptor-mediated superoxide anion production by human polymorphonuclear leukocytes via a soluble inhibitor. Am J Respir Cell Mol Biol1990; 2: 235–43.
76.
KlebanoffSJ. Phagocytic cells: Products of oxygen metabolism. In: GallinJIGoldsteinIM. Inflammation: Basic principles and clinical correlates. New York: Raven Press, 1988: 391–444.
77.
JohnsonRJCouserWGChiEYAdlerSKlebanoffSJ. New mechanism for glomerular injury. Myeloperoxidase-hydrogen peroxide-halide system. J Clin Invest1987; 79: 1379–87.
78.
SavageCOSPottingerBEGaskinGPuseyCDPearsonJD. Myeloperoxidase (MPO) binds to cultured human umbilical vein endothelial cells (HUVEC) and is recognized by autoantibodies, P-ANCA, from patients with systemic vasculitis. J Am Soc Nephrol1991; 2: 604.
79.
ClarkRABorregaardN.Neutrophils autoinactivate secretory products by myeloperoxidase-catalyzed oxidation. Blood1985; 65: 375–81.
80.
KaoRCWehnerNGSkubitzKMGrayBHHoidalJR. Proteinase 3. A distinct human polymorphonuclear leukocyte proteinase that produces emphysema in hamsters. J Clin Invest1988; 82: 1963–73.
81.
BoriesDRaynalMCSolomonDH. Down-regulation of a serine proteinase, myeloblastin, causes growth arrest and differentiation of promyelocytic leukaemia cells. Cell1989; 59: 959–68.
82.
LeungDY. Clinical and immunologic aspects of Kawasaki disease. Immunodefic Rev1989; vmr-3: 261–71.
83.
NewburgerJWTakahashiMBurnsJC. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med1986; 315: 341–47.
LeungDYMChuETWoodNGradySMeadeRGehaRS. Immunoregulatory T cell abnormalities in mucocutaneous lymph node syndrome. J Immunol1983; 130: 2002–2004.
86.
MauryCPJSaloEPelkonenP.Circulating interleukin-1b in patients with Kawasaki disease. N Engl J Med1988; 319: 1670–71.
87.
FurukawaSMatsubaraTJujohK. Peripheral blood monocyte/macrophage and serum tumor necrosis factor in Kawasaki disease. Clin Immunol Immunopathol1988; 48: 247–51.
88.
MauryCPJSaloEPelkonenP.Elevated circulating tumor necrosis factor-a in patients with Kawasaki disease. J Lab Clin Med1989; 113: 651–54.
89.
RowleyAHShulmanSTPrebleOTPoieszBJEhrlichGDSullivanJR. Serum interferon concentrations and retroviral serology in Kawasaki syndrome. Pediatr Infect Dis J1988; 7: 663–66.
90.
UenoYTakanoNKaneganeH. The acute phase nature of interleukin 6: Studies in Kawasaki disease and other febrile illness. Clin Exp Immunol1986; 76: 337–42.
91.
LeungDYMCotranRSKurt-JonesEA. Endothelial activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease. Lancet1989; 2: 1298–1302.
92.
KanekoKSavageCOSPottingerBEShahVPearsonJDDillonMJ. Antiendothelial cell antibodies can be cytotoxic to endothelial cells without cytokine pre-stimulation and correlate with ELISA antibody measurement in Kawasaki disease. J Am Soc Nephrol1991; 2: 598.
93.
ChanTMFramptonGJayneDRWPerryGJLockwoodCMCameronJS, Vasculitis sera stimulate von Willebrand factor (vWF) secretion by human endothelial cells in culture. J Am Soc Nephrol1991; 2: 590.
94.
TannenbaumSHFinkoRCinesDB. Antibody and immune complexes induce tissue factor production by human endothelial cells. J Immunol1986; 137: 1532–37.
95.
SavageCOSNgYC. The aetiology and pathogenesis of major systemic vasculitides. Postgrad Med J1986; 62: 627–36.